These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15314497)

  • 1. Remittive agents in pediatric rheumatology.
    Singer NG; Scalzi LV
    Curr Opin Rheumatol; 2004 Sep; 16(5):571-6. PubMed ID: 15314497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab in rheumatic diseases.
    Rath E; Zwerina J; Oppl B; Nell-Duxneuner V
    Wien Med Wochenschr; 2015 Jan; 165(1-2):28-35. PubMed ID: 25676699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
    Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
    Arthritis Rheumatol; 2017 Aug; 69(8):1538-1551. PubMed ID: 28620948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies in pediatric rheumatic diseases.
    Chira P; Sandborg CI
    Curr Opin Pediatr; 2003 Dec; 15(6):579-85. PubMed ID: 14631203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics in pediatric rheumatology.
    Becker ML
    Curr Opin Rheumatol; 2012 Sep; 24(5):541-7. PubMed ID: 22732686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International research networks in pediatric rheumatology: the PRINTO perspective.
    Ruperto N; Martini A
    Curr Opin Rheumatol; 2004 Sep; 16(5):566-70. PubMed ID: 15314496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in pediatric rheumatology: January to March 2019.
    Kumar Patra P; Zaffar Banday A; Singh S
    Int J Rheum Dis; 2019 Jul; 22(7):1327-1330. PubMed ID: 31245911
    [No Abstract]   [Full Text] [Related]  

  • 11. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K; Al-Maini M
    Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologicals for children and adolescents in the treatment of rheumatic diseases].
    Huppertz HI
    Z Rheumatol; 2012 Sep; 71(7):583-9; quiz 590-1. PubMed ID: 22930109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New age of biological therapies in paediatric rheumatology.
    Sen ES; Ramanan AV
    Arch Dis Child; 2014 Jul; 99(7):679-85. PubMed ID: 24621445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rheumatology].
    Scherer HU; Burmester GR
    Internist (Berl); 2005 Aug; 46(8):882-91. PubMed ID: 15997385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on biologics in juvenile idiopathic arthritis.
    Ilowite NT
    Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.
    Niehues T; Horneff G; Michels H; Höck MS; Schuchmann L; ;
    Rheumatol Int; 2005 Apr; 25(3):169-78. PubMed ID: 15688190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug therapies for the pediatric rheumatic diseases.
    Bloom BJ
    Curr Opin Rheumatol; 2001 Sep; 13(5):410-4. PubMed ID: 11604597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.
    Okihiro A; Hasija R; Fung L; Cameron B; Feldman BM; Laxer R; Schneider R; Silverman E; Spiegel L; Yeung RSM; Tse SML
    Pediatr Rheumatol Online J; 2018 Mar; 16(1):17. PubMed ID: 29540190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.